Top Page
Q-linea AB
(Frankfurt:QLINEA)
Q-linea AB (QLINEA) vs. iShares MSCI Sweden ETF (EWD)
Q-linea AB Business Overview & Revenue Model
Q-linea AB Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.49M | 2.36M | 4.44M | 12.79M | 9.34M | 243.00K |
| Gross Profit | -8.95M | -11.11M | 995.00K | -21.38M | -25.03M | -32.02M |
| EBITDA | -167.30M | -195.40M | -210.99M | -252.69M | -218.48M | -211.02M |
| Net Income | -188.54M | -216.87M | -229.37M | -275.77M | -233.18M | -220.19M |
Balance Sheet | ||||||
| Total Assets | 201.00M | 147.99M | 231.98M | 207.39M | 466.63M | 412.23M |
| Cash, Cash Equivalents and Short-Term Investments | 82.71M | 25.66M | 81.89M | 72.62M | 166.03M | 306.89M |
| Total Debt | 49.20M | 151.21M | 20.56M | 20.93M | 79.00K | 331.00K |
| Total Liabilities | 71.55M | 175.45M | 42.34M | 45.76M | 35.84M | 32.03M |
| Stockholders Equity | 129.45M | -27.46M | 189.64M | 161.63M | 430.79M | 380.20M |
Cash Flow | ||||||
| Free Cash Flow | -180.37M | -187.49M | -236.86M | -268.11M | -267.02M | -250.53M |
| Operating Cash Flow | -176.87M | -182.50M | -228.52M | -250.86M | -255.05M | -237.31M |
| Investing Cash Flow | -2.64M | -5.04M | -7.77M | 315.25M | -23.82M | -32.30M |
| Financing Cash Flow | 241.59M | 131.27M | 245.41M | -6.60M | 283.81M | 253.78M |
Q-linea AB Technical Analysis
Q-linea AB Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
48 Neutral | 653.05M | -0.36 | -74.62% | ― | 3.57% | -925.35% | |
45 Neutral | 2.27B | -5.31 | 0.00% | ― | -92.57% | -7.72% | |
41 Neutral | €227.78M | ― | -190.21% | ― | 16.98% | 36.29% | |
41 Neutral | 175.97M | -0.87 | -202.81% | ― | 31.03% | 55.25% | |
36 Underperform | 226.29M | -2.71 | 0.00% | ― | 0.00% | -56.68% | |
32 Underperform | 419.49M | -2.47 | 0.00% | ― | 0.00% | -20.61% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
Q-linea AB Corporate Events
Q-linea AB has announced the initiation of two new clinical evaluations of its ASTar system in Saudi Arabia and Kuwait, in collaboration with AMICO Group. These evaluations aim to integrate ASTar into routine clinical use in the GCC region, enhancing patient outcomes and productivity in hospitals already familiar with rapid AST practices.
The most recent analyst rating on (SE:QLINEA) stock is a Hold with a SEK51.00 price target. To see the full list of analyst forecasts on Q-linea AB stock, see the SE:QLINEA Stock Forecast page.
Q-linea AB has announced a change in the number of shares and votes following the issuance of equalization shares and a reverse share split, resulting in a new total of 6,436,873 shares as of July 31, 2025. This restructuring is part of a broader financial strategy to optimize the company’s capital structure, with potential implications for shareholder value and market positioning.
BLASTID and Q-linea have announced a successful proof-of-concept for ultra-rapid diagnosis of bloodstream infections and sepsis, presented at the ADLM2025 Conference in Chicago. Their collaboration has resulted in technologies that significantly reduce the time to clinically actionable results from days to hours, potentially saving lives and reducing healthcare costs by providing faster and more accurate testing directly from whole blood samples.
Q-linea AB’s Q2 2025 interim report highlights significant progress in commercializing its ASTar platform, with increased sales and a reduced operating loss. The company secured five new contracted instruments, bringing the total to 14, and aims to reach 30-40 by year-end. The successful capital raise of SEK 250.3 million will support further expansion and innovation. Notable achievements include partnerships with major U.S. institutions and pharmaceutical companies, as well as strong endorsements from the ASM. These developments position Q-linea as a leading player in the rapid AST market, with a growing international footprint and a robust pipeline for future growth.
Q-linea AB announced a correction to its previously released timetable for a reverse share split, clarifying that the last trading day before the split is 11 July 2025, not 13 July 2025. The reverse share split will reduce the total number of shares significantly and will automatically adjust shareholders’ holdings via Euroclear Sweden AB, with no action required from shareholders. This strategic move is expected to streamline the company’s share structure, potentially enhancing market perception and shareholder value.
Q-linea AB has announced a reverse share split, consolidating 1,000 shares into one, effective from 15 July 2025. This move, which reduces the total number of shares significantly, is intended to adjust the share price and streamline the company’s equity structure, with no required action from shareholders as the process will be managed automatically by Euroclear Sweden AB.
During its annual general meeting, Q-linea AB resolved several key decisions, including the adoption of income statements and balance sheets without issuing dividends, and the discharge of liability for board members and the former CEO. The meeting also confirmed board and auditor appointments, approved remuneration guidelines, and initiated a reverse share split to optimize the share structure, potentially impacting shareholder value and market perception.
Q-linea AB has made significant progress in its 2025 plan, with 14 ASTar instrument placements year-to-date and a target of 30-40 placements by the end of 2025. The company is expanding its commercial reach across EMEA and the US, with notable adoption in Italy and ongoing evaluations in multiple countries. A successful capital raise and increasing interest in the ASTar platform highlight its growing market differentiation, as evidenced by independent research and clinical feedback showing improved treatment times.